Pentobarbital will minimize the level or influence of pimavanserin by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep track of. Prevent coadministration if possible. Keep an eye on for lowered pimavanserin efficacy. A rise in pimavanserin dosage may be essential. Monoamine oxidase inhibitors (MAOI) could inhibit barbiturate metabolism and extend barbiturate https://henrikk530ipv6.spintheblog.com/profile